Using a preclinical model of obesity and pre-diabetes, here we report that sacubitril/valsartan (sac/val; LCZ696), a combination of Ang II receptor blocker and neprilysin (NEP) inhibitor (ARNi), improved echocardiographic parameters of ventricular stiffness that were impaired in untreated ZO rats. Here, MME is linked to diabetes mellitus.